Arvinas to Present at 2024 ASCO Annual Congress

Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company focused on developing therapies that degrade disease-causing proteins, has announced that two of its abstracts have been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Congress. The event will be held from May 31 to June 4, 2024, in Chicago, Illinois. 

The first abstract pertains to ARV-766, a proteolysis targeting chimera (PROTAC) designed to degrade the androgen receptor (AR) in metastatic castration-resistant prostate cancer (mCRPC). The findings from Phase 1/2 clinical trials will be presented on June 3, 2024, under the Genitourinary Cancer category. 

The second abstract is related to TACTIVE-K, a Phase 1b/2 study focusing on vepdegestrant, another PROTAC designed to target and degrade the estrogen receptor (ER) in combination with Pfizer’s investigational CDK4 inhibitor, atirmociclib (PF-07220060). This study targets ER+/HER2- advanced breast cancer and will be presented on June 2, 2024, during the Breast Cancer—Metastatic session.

ARV-766 is an investigational oral PROTAC protein degrader that selectively targets and degrades AR, showing promise in preclinical models of wild-type AR tumors and those with AR mutations or amplification. These mutations are common resistance mechanisms against existing AR-targeted therapies. In April 2024, Arvinas entered into an exclusive license agreement with Novartis for the global development and commercialization of ARV-766. The transaction's completion is pending customary conditions, including the expiration or termination of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period.

Vepdegestrant, also an investigational oral PROTAC protein degrader, targets the ER for treating ER+/HER2- breast cancer. Arvinas and Pfizer are co-developing vepdegestrant under a global collaboration initiated in July 2021. This partnership involves shared development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation for monotherapy in treating adults with ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine-based therapy.

Arvinas is dedicated to improving the lives of patients with debilitating and life-threatening diseases through its proprietary PROTAC Discovery Engine platform. This platform engineers PROTAC protein degraders that leverage the body's natural protein disposal system to selectively and efficiently degrade disease-causing proteins. Beyond its preclinical pipeline, Arvinas has four investigational clinical-stage programs: vepdegestrant for ER+/HER2- breast cancer, ARV-766 and bavdegalutamide for metastatic castration-resistant prostate cancer, and ARV-102 for neurodegenerative disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!